APW
RLMD icon

Acima Private Wealth’s Relmada Therapeutics RLMD Stock Holding History

Acima Private Wealth’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,844
Closed -$8.57K – 196
2024
Q1 		$8.57K Hold
1,844
– – ﹤0.01% 181
2023
Q4 		$7.63K Hold
1,844
– – ﹤0.01% 211
2023
Q3 		$5.53K Hold
1,844
– – ﹤0.01% 229
2023
Q2 		$4.54K Hold
1,844
– – ﹤0.01% 244
2023
Q1 		$4.17K Hold
1,844
– – ﹤0.01% 260
2022
Q4 		$6.44K Hold
1,844
– – ﹤0.01% 206
2022
Q3 		$68.3K Hold
1,844
– – 0.04% 147
2022
Q2 		$35K Buy
+1,844
New +$40.2K 0.02% 171

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acima Private Wealth's RLMD Position: Q2 2024 in Review

Acima Private Wealth sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 1,844 shares — an estimated $8.57K sold.

Acima Private Wealth first reported a position in RLMD in Q2 2022 and held it in 8 quarters. The position peaked at $68.3K in Q3 2022. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Acima Private Wealth reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Acima Private Wealth sold 1,844 Relmada Therapeutics shares in Q2 2024, an estimated $8.57K.
  • Acima Private Wealth first reported a position in Relmada Therapeutics in Q2 2022 and held it in 8 quarters.
  • Acima Private Wealth's Relmada Therapeutics position peaked at $68.3K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Acima Private Wealth's 13F filing for Q2 2024, filed 30 Jul 2024.